1-芳基-4-乙氧羰基-5-氨基-1,2,3,-连三唑和几种亲电子试剂的反应及产物抗菌性能的研究

本文研究1-芳基-4-乙氧羰基-5-氨基-1,2,3,-连三唑(1)同过量乙酸,乙酸酐、乙酰氯、苯甲酰氯以及甲酰胺等的反应,制得1的14种新衍生物:1-H-4-乙氧羰基-5-芳胺基-1,2,3-连三唑(2 b～d),1-酰基-4-乙氧羰基-5-芳胺基-1,2,3-连三唑(3a～d),1-芳基-4-乙氧羰基-5-乙酰胺基-1,2,3-连三唑-(4a～d)以及1-甲酰基-4-乙氧羰基-5-对硝基苯胺基-1,2,3-连三唑(5a),1-苯甲酰基-4-乙氧羰基-5-对硝基苯胺基-1,2,3-连三唑(5b),1-对氨苯甲酰基-4-乙氧羰基-5-对硝基苯胺基-1,2,3-连三唑(5c)。所有化合物的结构,均经元素分析及波谱分析确证,并筛选了一些化合物的抗菌作用。     

N-芳酰基取代的二氢吲哚-3-乙酸类衍生物的设计、合成与体外降糖活性研究

目的:设计、合成N-芳酰基取代的二氢吲哚-3-乙酸类衍生物,并评价其体外降糖活性。方法:以吲哚衍生物2-[5-(苄氧基)-1-(4-氯苯甲酰基)-2-甲基-1H-吲哚-3-基]乙酸(GY3)为先导化合物,以4-苯甲氧基苯肼盐酸盐及4-氧戊酸甲酯为原料,经Fischer吲哚环合、还原、酰胺化及水解等4步反应得到8种N-芳酰基(3-羟基苯甲酰基、3-氰基苯甲酰基、4-硝基苯甲酰基、4-甲磺酰基苯甲酰基、4-乙酰胺基苯甲酰基、3-乙酰氨基苯甲酰基、异烟酰基、吡啶-2-甲酰基)取代的二氢吲哚-3-乙酸类衍生物。采用人肝癌细胞HepG2测试目标化合物的体外促葡萄糖消耗活性。结果:共合成8个N-芳酰基取代的二氢吲哚-3-乙酸类目标化合物,其结构均经质谱、核磁共振氢谱及碳谱确证。在1.0μmol/L条件下,所合成化合物在HepG2细胞上的促葡萄糖消耗百分率为5.4%～9.1%,其中,2-[(2R,3S)-5-苄氧基-2-甲基-1-(4-甲磺酰基苯甲酰基)-2,3-二氢-吲哚-3-基]乙酸的降糖活性最好,其促葡萄糖消耗百分率为(9.10±1.81)%,与阳性对照药物二甲双胍接近[(10.58±1.68)%],但仍弱于先导化合物GY3[(12.15±0.78)%]。结论:二氢吲哚类化合物的N-芳酰基芳环上引入不同吸电子取代基团,如氰基、硝基、甲磺酰基等,其降糖活性不同程度下降,且弱于卤素取代基的GY3。     

2-芳基烷酸类非甾体消炎药的新合成法

前已报道,烷基芳酮(ArCOCHRR~1)通过与吡咯烷、叠氮磷酸二苯酯(DPPA,4d)和氢氧化钾三步反应,能简捷地制取2-芳基烷酸(ArCRR~1CO_2H)。本文报道,用相同反应成功地制得具2-芳基丙酸骨架的一系列非甾体消炎药:布洛芬(Ibuprofen 1a)、萘普生(Naproxen 1b)、酮基布洛芬(Ketoprofen 1e)、氟联苯布洛芬(Flurobiprofen ld),以及2-(2-二苯并呋喃基)丙酸(1e),后者是制备2-(杂芳基)丙酸的例子。最初应用几种磷的叠氮化物(4a～c),均似相应的氯化物和叠氮化钠反应得到。经试     

1-[(5-硝基呋喃甲叉)胺基]-4-眯唑啉-2-酮类的衍生物

已发现,1-[(5-硝基呋喃甲叉)胺基]-4-咪唑啉-2-酮(1)是 nifuradene 的降解产物并具有抗菌作用,从而促进了一系列取代衍生物的合成。化学上,N-羟甲基化合物(2)系通过(1)以甲醛溶液处理而得,N-甲基衍生物(3)的制备可根据前已报道的(1)的制备方法进行,但以 N-甲胺基乙醛缩二乙醇替代氨基乙醛缩二乙醇。4-芳基化合物(4)和(5)是在5-硝基-2-糠醛存在下,分别由1-乙酰胺基-4-(4-硝基苯)-4-咪唑啉-2-酮和1-乙酰胺基-4-     

新型缩氨基硫脲衍生物——氨基巯三唑Schiff碱的合成与抗菌活性

设计合成了新型缩氨基硫脲衍生物4-氨基-3-(呋喃-2)-5-巯基-1,2,4-三唑及其十种不同醛的Schiff碱衍生物,并进行了抑菌实验。结果表明:Schiff碱化合物结构中的甲亚胺基是该类化合物的活性功能基。苯环上更换不同的取代基对其活性有一定的影响,其中化合物4-(5-硝基亚糠基氨基)-3-(呋喃-2)-5-巯基-1,2,4-三唑(Ik)抗菌活性最高且抗菌谱最广;化合物4-亚水杨基氨基-3-(呋喃-2)-5-巯基-1,2,4-三唑(Ib)具有较强的抑霉活性。     

新型缩氨基硫脲衍生物——氨基巯三唑Schiff碱的合成与抗菌活性

设计合成了新型缩氨基硫脲衍生物4-氨基-3-(呋喃-2)-5-巯基-1,2,4-三唑及其十种不同醛的Schiff碱衍生物,并进行了抑菌实验。结果表明:Schiff碱化合物结构中的甲亚胺基是该类化合物的活性功能基。苯环上更换不同的取代基对其活性有一定的影响,其中化合物4-(5-硝基亚糠基氨基)-3-(呋喃-2)-5-巯基-1,2,4-三唑(Ik)抗菌活性最高且抗菌谱最广;化合物4-亚水杨基氨基-3-(呋喃-2)-5-巯基-1,2,4-三唑(Ib)具有较强的抑霉活性。     

4-取代苯胺基-1,2,3-苯并三嗪类化合物的合成及其抑制MVEC细胞增殖活性

目的设计合成4-取代苯胺基-1,2,3-苯并三嗪类化合物,并测定其体外抗增殖活性。方法以4-羟基-3-甲氧基苯甲腈为原料,经成醚、硝化、硝基还原制得中间体4-烷氧基-2-氨基-5-甲氧基苯甲腈,该中间体或邻氨基苯甲腈与不同取代的苯胺发生重氮化-偶合反应后再经环合、Dimroth重排反应得到目标化合物;采用MTT法,以瓦他拉尼(vatalanib)为阳性对照药,测试目标化合物对大鼠脑微血管内皮细胞(MVEC)的抗增殖活性。结果与结论合成了15个新化合物,其结构经IR、MS、1H-NMR谱确证;初步药理实验结果显示,2个目标化合物具有明显的抗MVEC增殖活性,其中,化合物7d的活性强于阳性对照,其GI50值为16.34μmol·L-1。     

n-(4-芳酰胺基苯基)甲磺酰胺类化合物的合成及抗炎活性

目的研究n-(4-芳酰胺基苯基)甲磺酰胺类化合物的抗炎作用。方法以对硝基苯胺为起始原料经三步反应合成目标化合物，并以二甲苯致小鼠耳肿胀模型测试目标化合物的抗炎活性。结果共合成11个化合物，经IR，¹HNMR和MS光谱确证结构；初步药理试验结果显示大部分化合物对二甲苯致小鼠耳肿胀具有较强的抑制作用。结论n-(4-芳酰胺基苯基)甲磺酰胺类化合物具有较强的抗炎活性。     

新型3-草酰胺-2-苯基吲哚衍生物的合成及其黄体细胞生长抑制活性的研究(英文)

本文报道以苯肼为原料合成了6个2-苯基-3-草酰胺基吲哚衍生物1a～f,其结构均未见文献报道。经初步体外试验结果表明,所被测试的6个目标化合物均具一定的离体黄体细胞生长抑制活性,且2-(4-甲氧苯基)吲哚化合物1b～d的活性明显高于2-苯基吲哚化合物1a。但在1b的吲哚氮上引入甲基或异丙基对活性没有影响。     

基于反向找靶的3-芳基-5-芳甲酰胺基吡唑-4-乙酰胺衍生物的设计合成及抗肿瘤活性研究

目的运用Discovery Studio 2018软件的反向找靶功能,对设计的一类3-芳基-5-芳甲酰胺基吡唑-4-乙酰胺衍生物进行药物潜在靶点预测和筛选。方法以取代的苯甲酸甲酯为起始原料,经过亲核加成-消除、亲核取代、缩合等四步反应得到目标化合物。根据靶点筛选结果,用MTT法对其体外抗肿瘤活性进行初步筛选。结果与结论共合成了10个目标化合物,均为新化合物,其结构经~1H-NMR、~(13)C-NM R及HRMS谱确证。化合物5a～5h均具有一定的抗肿瘤活性,其中化合物5h的活性最佳,对人骨肉瘤细胞Saos-2和U-2 OS的抗增殖活性的IC_(50)值分别是1. 3μmol·L~(-1)和0. 9μmol·L~(-1)。     

Synthesis and evaluation of anti-inflammatory activity of some thiazolo[3,2-b]-1,2,4-triazole-5(6H)-ones and their Michael addition products

Thiazolo[3,2-b]-1,2,4-triazole-5(6H)-ones (4-10) were obtained in a one step synthesis by heating 3-aryl-5-mercapto-1,2,4-triazoles (3a-d) with chloroacetic acid and appropriate aromatic aldehyde in acetic acid and acetic anhydride in the presence of anhydrous NaOAc. Michael type addition of cyclic secondary amines (N-methylpiperazine, piperidine) to 4-10 gave 2-phenyl-6-(alpha-aminoarylmethyl)thiazolo[3,2-b]-1,2,4-triazole-5 -ols (4a-10b). The structures of the compounds were confirmed by spectral and elementary analysis. The compounds synthesized in previous and present studies were investigated for their anti-inflammatory activities.     

Heterocyclen, 65. Mitt.: Darstellung und chemisches Verhalten einiger 2-Aryl-6-ethoxycarbonyl-5-methyl-thiazolo[3,2-b]-1,2,4-triazole

Heterocycles, LXV: Synthesis and Chemical Characterization of Some 2-Aryl-6-ethoxycarbonyl-5-methyl-thiazolo[3,2-b]-1,2,4-triazoles The syntheses of some 2-aryl-6-ethoxycarbonyl-5-methyl-thiazolo[3,2-b]-1,2,4-triazoles and their chemical and spectroscopic properties (IR, UV, MS) are described.     

Novel pyrazole derivatives as potential promising anti-inflammatory antimicrobial agents

Four series of 1H-pyrazole derivatives have been synthesized. The first series was synthesized starting by condensing the hydrazine derivatives 1a-d with 4-(1-ethoxycarbonyl-2-oxopropyl)azobenzoic acid 2a in ethanol or glacial acetic acid to generate the corresponding pyrazoline derivatives 3a-d. Likewise, heating 1a-d with 4-(1-acetyl-2-oxopropyl)azobenzoic acid 2b gave rise to the pyrazole derivatives 4a-d. Similarly, reaction of 1a-d with ethyl 2-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-ylazo)-3-oxobutanoate 2c or 3-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl azo)pentane-2,4-dione 2d in ethanol or glacial acetic acid led to the corresponding pyrazoline derivatives 5a-d or pyrazole derivatives 6a-d. The newly synthesized compounds were evaluated for their anti-inflammatory-antimicrobial activities. In addition, the ulcerogenic and acute toxicity profiles were determined. Compound 6c, proved to be the most active anti-inflammatory-antimicrobial agent in the present study with a good safety margin and no ulcerogenic effect.     

Triazolines. 14. 1,2,3-Triazolines and triazoles, a new class of anticonvulsants. Drug design and structure-activity relationships

Pioneering studies in our laboratories have led to the emergence of the delta 2-1,2,3-triazolines (4,5-dihydro-1H-1,2,3-triazoles) and the closely related 1H-1,2,3-triazoles as a unique family of anticonvulsant agents hitherto unknown. Unlike the traditional anticonvulsants, the dicarboximide moiety is absent from the traiazoline ring system. This paper examines the results of evaluation of several groups of 1-aryl-5-pyridyl-substituted triazolines and triazoles with particular reference to structure-activity relationships in each compound group as well as between compounds in the different groups and the 1,5-diaryl compounds. The Topliss manual approach for application fo the Hansch method is employed for the rational design of triazoline/triazole anticonvulsants. Anticonvulsant activity was determined, after intraperitoneal administration, in two standard seizure models in the mouse, the MES and scMet tests. Central nervous system toxicity was evaluated in the rotorod ataxia test. Analysis of structure-activity relationships using the Topliss scheme indicated a clear pi + sigma dependency in the 1-aryl-5-(4-pyridyl)triazolines while an adverse steric effect (Es) from 4-substitution appeared to be present in the 1-aryl-5-(3-pyridyl) compounds. A similar but strong steric effect dominated the structure-activity pattern of the 1-aryl-5-(4-pyridyl)triazoles, although a sigma dependency was more evident in the 1-aryl-5-(3-pyridyl)- and the 1,5-diaryltriazole series. No significant activity was observed among the 1-aryl-5-(2-pyridyl)triazolines, and although the respective triazoles were active, the parameter dependency was not clearly defined. Similarly, the 1,5-diaryltriazolines, as a group, showed no pronounced anticonvulsant activity. However, replacement of the 5-aryl with a pyridyl group, particularly a 4-pyridyl, led to highly enhanced anticonvulsant activity. In addition, oxidation of triazolines with no anticonvulsant activity yielded, as a rule, triazoles that were active, which could be linked to their chemistry or structural conformation. The triazolines and triazoles evince anticonvulsant activity as a class and compare very well with the prototype antiepileptic drugs--ethosuximide, phenytoin, phenobarbital, valproate--in their anticonvulsant potency and minimal neurotoxicity. They have emerged as a new generation of anticonvulsant agents that show great promise as potentially useful antiepileptic drugs.     

Novel 3,3a,4,5,6,7-hexahydroindazole and arylthiazolylpyrazoline derivatives as anti-inflammatory agents

A novel series of 7-benzylidene-3, 3a, 4, 5, 6, 7-hexahydro-3-phenyl-2H-indazole substituted at the 2-position were synthesized. The reaction of 2, 6-bis-benzylidenecyclohexanone (1) with thiosemicarbazide in the presence of NaOH afforded a mixture of the 3-H, 3a-H trans 2 and cis 2a diastereoisomers which have been separated by fractional recrystallization. Interaction of the first intermediate 2 with substituted phenacyl bromides, aromatic aldehydes and chloroacetic acid in presence of a mixture of acetic acid and acetic anhydride, and 2, 3-dichloroquinoxaline yielded the corresponding 7-benzylidene-3, 3a, 4, 5, 6, 7-hexahydro-3-phenyl-2H-indazole derivatives substituted at the 2-position with 4-aryl-2-thiazolyl 3a, b, 5-arylidene-4, 5-dihydro-4-oxo-2-thiazolyl 4a, b and thiazolo[4, 5-b]quinoxalin-2-yl 5, respectively. Moreover, the other intermediates 3, 5-diaryl-1-thiocarbamoyl-2-pyrazolines 7a-d were reacted with the previously-mentioned reagents and gave the corresponding 3, 5-diaryl-1-(4-aryl-2-thiazolyl)-2-pyrazolines 8a-h, 3, 5-diaryl-1-(5-arylidene-4, 5-dihydro-4-oxo-2-thiazolyl)-2-pyrazolines 9a-d and 3, 5-diaryl-1-(thiazolo[4, 5-b]quinoxalin-2-yl)-2-pyrazoline derivatives 10a, b, respectively. Some of the newly prepared compounds were subjected to evaluation for their anti-inflammatory activity. The structures of the new compounds were confirmed by elemental analyses as well as (1)H-NMR, IR, and MS data.     

Synthesis of some triazolophthalazine derivatives for their anti-inflammatory and antimicrobial activities

Several novel series of triazolophthalazine derivatives namely; pyrazolylethenyltriazolophthalazinones (4a-d), styryltriazolophthalazinones (5a,b), aryloxopropenyltriazolophthalazinones (7a,b), pyrazolinyl- (8a,b), (9a,b) and (10a-f), pyrazolyl- (11a-d), (1,2-oxazol-5-yl)-1,2,4-triazolo[3,4-a]phthalazin-6(5H)-ones (14a,b), triazolo[3,4-a]phthalazin-3-yl-pyridine-3-carbonitriles (12a,b), triazolo[3,4-a]phthalazin-3-yl)ethylthioacetic acids (13a,b) and 2-aryl-5-arylamino-1H,5H-pyrazolo[2″,3″-1',5']imidazo[3',4'-1,5]-1,2,4-triazolo[3,4-a]phthalazin-12(13H)-ones (15a-c) have been synthesized. The anti-inflammatory activity of representative compounds has been studied. Compounds 8b, 10c, 10f, 11b, 12a, 13b, and 15a showed anti-inflammatory activities comparable to that of the reference standard, indomethacin. They exhibit also minimal ulcerogenic effect relevant to the reference standard and were found to be non-toxic up to 120 mg/kg orally or up to 75 mg/kg through parenteral route. Concerning the antimicrobial activity; compounds 12b and 13b were found to be equipotent to ampicillin against Staphylococcus aureus, while compounds 10a and 10f were found to be as potent as ampicillin against E. coli, whereas compound 14b exhibited equipotency to clotrimazole against Candida albicans. Compounds 8b, 10f, 11b, 12a, and 13b exhibited, besides their antimicrobial activity, moderate to potent anti-inflammatory profiles. This represents a fruitful matrix for the development of a new class of dual non-acidic anti-inflammatory/antimicrobial agents.     

Alkylating nucleosides 1. Synthesis and cytostatic activity of N-glycosyl(halomethyl)-1,2,3-triazoles. A new type of alkylating agent.

1,3-Dipolar cycloaddition of benzyl azide or peracetylated glucopyranosyl azides to propargyl halides or 1,4-dihalobutynes yielded 1-benzyl- or 1-glycosyl(halomethyl)-1,2,3-triazoles. Alkylating chloromethyl- bromomethyl- and iodomethyl-1,2,3-triazoles were also obtained from the corresponding hydroxymethyl derivatives by treatment with (C6H5)3P/CCl4, (C6H5O)3P/Br2, and (C6H5O)3P/I2, respectively. 1-Benzyl-4-(fluoromethyl)-1,2,3-triazole was obtained from 1-benzyl-4-(bromomethyl)-1,2,3-triazole by treatment with KF and 18-crown-6. Chloromethyl-, bromomethyl-, and iodomethyl-1,2,3-triazole derivatives inhibited the "in vitro" growth of HeLa cells. Some of these compounds increased the life span of mice bearing tumors.     

One-pot tandem copper-catalyzed library synthesis of 1-thiazolyl-1,2,3-triazoles as anticancer agents

One-pot multicomponent synthesis to assemble compounds has been an efficient method for constructing a compound library. We have developed one-pot tandem copper-catalyzed azidation and CuAAC reactions that afford 1-thiazolyl-1,2,3-triazoles with anticancer activity. By utilizing this one-pot synthetic strategy, we constructed a library of 1-thiazolyl-1,2,3-triazoles in search of the potent lead compound. Furthermore, 1-thiazolyl-1,2,3-triazoles were evaluated for anticancer activity against the multidrug-resistant cancer cells MES-SA/Dx5. Most of the 1-thiazolyl-1,2,3-triazoles revealed cytotoxic effect against cancer cells at micromolar to low micromolar range. Testing some of the most potent compounds (5{4,2-4} and 5{5,1-3}) against the normal cell line Vero showed no significant toxicity (except 5{4,2}) to normal cells. This result indicates that compounds 5{4,3-4} and 5{5,1-3} possessed good potency and selectivity to cancer cells over normal cells.     

Synthesis and antihyperlipidemic activity of some novel 4-(substitutedamino)-5-substituted-3-mercapto- (4H)-1,2,4-triazoles

Hyperlipidemia is considered one of the key factors for cardiovascular diseases. Based on earlier work on a series of 5-alkyl-4-aryl-3-mercapto-(4H)-1,2,4-triazoles, for further lead modification, a series of 4-(substituted)amino-5-substituted-3-mercapto-(4H)-1,2,4-triazoles was designed. Target compounds were synthesized by the well known Hoggarth synthesis of substituted 1,2,4-triazoles. Synthesized compounds were screened for lipid lowering activity using the "Poloxamer 407 induced hyperlipidemia in rats" model at a dose of 100 mg/kg p.o. Compounds were found to alter serum lipid levels significantly. Most of the compounds significantly reduced serum cholesterol and triglyceride levels. Some of the compounds were found to reduce triglycerides and elevate high density lipoprotein (HDL) levels more than the standard drug atorvastatin (CAS 134523-03-8). Compounds with chloro substitution on aryl rings were found more active in reducing serum lipid levels than other substitutions.     

Synthesis and antimicrobial evaluation of some 6-aryl-5-cyano-2-thiouracil derivatives

A series of 6-aryl-5-cyano-2-thiouracil derivatives (1a-d) was synthesized by the reaction of ethyl cyanoacetate with thiourea and aldehydes. These products were used as intermediate compounds for the synthesis of a number of thiouracil derivatives (2a-d to 10a-d). All compounds were screened for antibacterial and antifungal activities. Some of the prepared compounds, 6-(4-fluorophenyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide (2a), 4-oxo-2-thioxo-6-(3,4,5-trimethoxyphenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (2d), 6-(4-fluorophenyl)-4-hydrazino-2-thioxo-1,2-dihydropyrimidine-5-cabonitrile (7a) and 4-hydrazino-2-thioxo-6-(3,4,5-trimethoxyphenyl)-1,2-dihydropyrimidine-5-carbonitrile (7d) revealed promising antimicrobial activity.